According to relevant regulations of No.7 Guidance for Information Disclosure of Listed Companies for pharmaceutical manufacture sector, the company, who will get the summary report about a clinic trial, should disclose relevant information about the medicine, project investment, development progress and marketing status in time.
Tasly Phar. Group Co.,Ltd hereby declares that all clinical development phase of Dantonic (T89) for us FDA clearance have been completed. The site closure visit procedure for the pivotal phase Ⅲ trial is in progress.
The final trial result will be released when the summary report of the clinical trial is available after database locking, data analysis and unblind steps.
Tianjin Tasly Pharmaceutical Co. Ltd. issued this content on 29 March 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 30 March 2016 16:25:18 UTC
Original Document: http://www.tasly.com/show.aspx?id=11123&cid=22